Bar-Hai Neta, Ishay-Ronen Dana
Cancer Research Center, Oncology Institute, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Affiliated with Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Front Pharmacol. 2022 Aug 11;13:944773. doi: 10.3389/fphar.2022.944773. eCollection 2022.
Cancer is a systemic heterogeneous disease that can undergo several rounds of latency and activation. Tumor progression evolves by increasing diversity, adaptation to signals from the microenvironment and escape mechanisms from therapy. These dynamic processes indicate necessity for cell plasticity. Epithelial-mesenchymal transition (EMT) plays a major role in facilitating cell plasticity in solid tumors by inducing dedifferentiation and cell type transitions. These two practices, plasticity and dedifferentiation enhance tumor heterogeneity creating a key challenge in cancer treatment. In this review we will explore cancer cell plasticity and elaborate treatment modalities that aspire to overcome such dynamic processes in solid tumors. We will further discuss the therapeutic potential of utilizing enhanced cell plasticity for differentiation therapy.
癌症是一种全身性异质性疾病,可经历多轮潜伏期和激活期。肿瘤进展通过增加多样性、适应微环境信号以及治疗逃逸机制而演变。这些动态过程表明细胞可塑性的必要性。上皮-间质转化(EMT)在实体瘤中通过诱导去分化和细胞类型转变,在促进细胞可塑性方面发挥主要作用。可塑性和去分化这两种特性增强了肿瘤异质性,给癌症治疗带来了关键挑战。在本综述中,我们将探讨癌细胞可塑性,并阐述旨在克服实体瘤中此类动态过程的治疗方式。我们还将进一步讨论利用增强的细胞可塑性进行分化治疗的潜在疗法。